Abstract

Breast cancer remains a major global health challenge, demanding better diagnostic tools. Traditional methods like mammography have limitations, highlighting the need for specific, non-invasive approaches. Protein biomarkers offer a promising avenue for early and accurate detection, potentially leading to improved patient outcomes and personalized treatment. This review explores key protein biomarkers, including Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER-2), and Cancer Antigen 27.29(CA27.29), focusing on the proteomic methodologies used in their discovery and validation. However, challenges exist, such as variability in biomarker expression and limitations in abundance, stability, and specificity, which hinder clinical use. The review discusses innovative strategies to overcome these challenges, emphasizing the importance of translating biomarker research into practical applications for personalized medicine in breast cancer diagnosis and therapy. This exploration contributes to the evolving field of breast cancer diagnostics, paving the way for future discoveries and improved patient care.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.